Anesthesia Considerations for a Patient on Semaglutide and Delayed Gastric Emptying DOI Open Access

Erina Fujino,

Kathryn W Cobb,

Jay Schoenherr

и другие.

Cureus, Год журнала: 2023, Номер unknown

Опубликована: Июль 19, 2023

Semaglutide is a class of long-acting glucagon-like peptide-1 receptor agonists (GLP1-RA) used for the treatment type 2 diabetes mellitus (T2DM) and obesity. We present 31-year-old female patient with past medical history T2DM without complication no long-term or current use insulin, 3 obesity, hypertension, hyperlipidemia, polycystic ovary syndrome (PCOS), anxiety, who underwent an esophagogastroduodenoscopy (EGD) in preparation bariatric surgery while taking semaglutide. Despite appropriately following preoperative fasting guidelines American Society Anesthesiologists (ASA), endoscopy revealed food residue gastric body, necessitating abortion procedure to reduce risk intraoperative pulmonary aspiration. Given lack patients on semaglutide date, delayed emptying being known side effect among semaglutide, anesthesiologists should be aware alternative methods ensure stomach mitigate aspiration during general anesthesia.

Язык: Английский

Relationship between perioperative semaglutide use and residual gastric content: A retrospective analysis of patients undergoing elective upper endoscopy DOI
Saullo Queiroz Silveira, Leopoldo Muniz da Silva,

Arthur de Campos Vieira Abib

и другие.

Journal of Clinical Anesthesia, Год журнала: 2023, Номер 87, С. 111091 - 111091

Опубликована: Март 2, 2023

Язык: Английский

Процитировано

154
Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review DOI Open Access
Mojca Jensterle, Manfredi Rizzo, Martin Haluzı́k

и другие.

Advances in Therapy, Год журнала: 2022, Номер 39(6), С. 2452 - 2467

Опубликована: Май 3, 2022

Язык: Английский

Процитировано

136
Semaglutide for the treatment of overweight and obesity: A review DOI Creative Commons
Natasha C. Bergmann, Melanie J. Davies, Ildiko Lingvay

и другие.

Diabetes Obesity and Metabolism, Год журнала: 2022, Номер 25(1), С. 18 - 35

Опубликована: Окт. 18, 2022

Obesity is a chronic, relapsing disease associated with multiple complications and substantial morbidity, mortality health care burden. Pharmacological treatments for obesity provide valuable adjunct to lifestyle intervention, which often achieves only limited weight loss that difficult maintain. The Semaglutide Treatment Effect in People (STEP) clinical trial programme evaluating once-weekly subcutaneous semaglutide 2.4 mg (a glucagon-like peptide-1 analogue) people overweight or obesity. Across STEP 1, 3, 4 8, was mean losses of 14.9%-17.4% individuals without type 2 diabetes from baseline week 68; 69%-79% participants achieved ≥10% (vs. 12%-27% placebo) 51%-64% ≥15% 5%-13% placebo). In 5, -15.2% versus -2.6% placebo 104. (individuals obesity, diabetes), -9.6% -3.4% 68. Improvements cardiometabolic risk factors, including high blood pressure, atherogenic lipids benefits on physical function quality life were seen mg. safety profile consistent across trials, primarily gastrointestinal adverse events. magnitude reported the trials offers potential clinically relevant improvement obesity-related diseases.

Язык: Английский

Процитировано

121
Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report DOI

Sandra R. Klein,

Ion A. Hobai

Canadian Journal of Anesthesia/Journal canadien d anesthésie, Год журнала: 2023, Номер 70(8), С. 1394 - 1396

Опубликована: Март 28, 2023

Процитировано

107
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity DOI Open Access
Daniel J. Drucker

Diabetes Care, Год журнала: 2024, Номер unknown

Опубликована: Июнь 6, 2024

The development of glucagon-like peptide 1 receptor agonists (GLP-1RA) for type 2 diabetes and obesity was followed by data establishing the cardiorenal benefits GLP-1RA in select patient populations. In ongoing trials investigators are interrogating efficacy these agents new indications, including metabolic liver disease, peripheral artery Parkinson Alzheimer disease. success GLP-1–based medicines has spurred molecular entities combinations with unique pharmacokinetic pharmacodynamic profiles, exemplified tirzepatide, a GIP-GLP-1 coagonist. Simultaneously, investigational molecules such as maritide block GIP activate GLP-1 receptor, whereas retatrutide survodutide enable simultaneous activation glucagon receptors. Here I highlight evidence medicines, while discussing that inform safety, focusing on muscle strength, bone density fractures, exercise capacity, gastrointestinal motility, retained gastric contents anesthesia, pancreatic biliary tract disorders, risk cancer. Rapid progress highly efficacious anticipated differentiation newer subsets will provide greater opportunities use personalized medicine approaches to improve health people living cardiometabolic disorders.

Язык: Английский

Процитировано

96
New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics DOI Creative Commons
Ania M. Jastreboff, Robert F. Kushner

Annual Review of Medicine, Год журнала: 2023, Номер 74(1), С. 125 - 139

Опубликована: Янв. 27, 2023

Nearly half of Americans are projected to have obesity by 2030, underscoring the pressing need for effective treatments. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) represent first agents in a rapidly evolving, highly promising landscape nascent hormone-based therapeutics. With understanding neurobiology expanding, these emerging entero-endocrine and endo-pancreatic combined or coformulated with GLP-1 RAs herald new era targeted, mechanism-based treatment obesity. This article reviews previews imminent future nutrient-stimulated anti-obesity

Язык: Английский

Процитировано

90
Association of glucagon‐like peptide‐1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy DOI Creative Commons

Toshiko Kobori,

Yukiko Onishi, Yoko Yoshida

и другие.

Journal of Diabetes Investigation, Год журнала: 2023, Номер 14(6), С. 767 - 773

Опубликована: Март 15, 2023

Previous studies have reported that the glucagon-like peptide-1 receptor agonist (GLP-1RA) delays gastric emptying, and emptying was assessed by 13 C breath test or paracetamol absorption technique. However, neither of them is clinically familiar in real-world clinical practice. The purpose present study to investigate association between GLP-1RA treatment residue an esophagogastroduodenoscopy.This a matched pair case-control study. population consisted 1,128 individuals with diabetes who had esophagogastroduodenoscopy at our clinic July 2020 June 2022. To account for differences characteristics, such as age, sex, insulin glycated hemoglobin, we carried out one-to-one nearest neighbor propensity score matching analysis patients without treatment. After matching, compared presence McNemar treatment.After selected 205 pairs. In score-matched comparison, proportion statistically significantly higher group (0.49% vs 5.4%, P = 0.004). details prescribed 11 were liraglutide once daily 1.8 mg (n 2), dulaglutide weekly 0.75 5), semaglutide 0.5 2) 1.0 2).GLP-1RA associated diabetes.

Язык: Английский

Процитировано

84
Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound: a prospective observational study in volunteers without obesity recently started on semaglutide DOI
Marc Sherwin,

Joshua Hamburger,

Daniel Katz

и другие.

Canadian Journal of Anesthesia/Journal canadien d anesthésie, Год журнала: 2023, Номер 70(8), С. 1300 - 1306

Опубликована: Июль 19, 2023

Язык: Английский

Процитировано

79
Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review DOI Open Access
Manoj K. Mahapatra, Muthukumar Karuppasamy,

Biswa Mohan Sahoo

и другие.

Pharmaceutical Research, Год журнала: 2022, Номер 39(6), С. 1233 - 1248

Опубликована: Июнь 1, 2022

Язык: Английский

Процитировано

73
Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial DOI Creative Commons
Simon Birk Kjær Jensen, Martin Bæk Blond, Rasmus Michael Sandsdal

и другие.

EClinicalMedicine, Год журнала: 2024, Номер 69, С. 102475 - 102475

Опубликована: Фев. 19, 2024

BackgroundNew obesity medications result in large weight losses. However, long-term adherence a real-world setting is challenging, and termination of medication results regain towards pre-treatment body weight. Therefore, we investigated whether loss improved composition are sustained better at 1 year after active treatment with glucagon-like peptide-1 (GLP-1) receptor agonist, supervised exercise program, or both combined for year.MethodsWe conducted post-treatment study extension randomised, controlled trial Copenhagen. Adults (aged 18–65 years initial mass index 32–43 kg/m2) completed an eight-week low-calorie diet-induced 13.1 kg (week −8 to 0) were randomly allocated (1:1:1:1) one-year maintenance 0–52) either exercise, the GLP-1 agonist once-daily subcutaneous liraglutide 3.0 mg, combination liraglutide, placebo. 166 Participants phase. All randomised participants invited participate outcome assessments one termination, week 104. The primary assessment was change from (at randomisation, 104) intention-to-treat population. secondary body-fat percentage 0–104). registered EudraCT, 2015-005585-32, ClinicalTrials.gov, NCT04122716.FindingsBetween Dec 17, 2018, 2020, 109 attended study. From randomisation 0–104), had reduced (−5.1 [95% CI −10.0; −0.2]; P = 0.040) (−2.3%-points [−4.3 −0.3]; 0.026) compared alone. More who previously received maintained least 10% placebo (odds ratio [OR] 7.2 [2.4; 21.3]) (OR 4.2 [1.6; 10.8]). 3.7 [1.2; 11.1]). During 52–104), 6.0 [2.1; 10.0] larger 2.5 [−1.5 6.5] treatment.InterpretationThe addition pharmacotherapy seems improve healthy Body contrast alone.FundingHelsefonden Novo Nordisk Foundation.

Язык: Английский

Процитировано

69